# BIOMARKERS & PRECISION MEDICINE 2025

## 30 September - 01 October 2025 | London, UK

**Uniting over 1,000 leading scientific researchers, pharmaceutical innovators, and healthcare professionals.**

Our Biomarkers, Digital Pathology & AI, and Spatial Biology in Precision Medicine programmes foster collaboration, drive knowledge exchange, and accelerate technological advancements to enhance precision medicine and transform patient outcomes.

**JULIA JONES**
Scientific Manager, Histopathology/ ISH Core Facility,
**Cancer Research UK - Cambridge Institute**

**ANDREW PIERCE**
Vice President - Translational Biology,
**Crescendo Biologics Limited**

**RADHA KRISHNAN**
Executive Director, Clinical Pathology Lead,
**MSD UK**

**GERARD SANDERINK**
Global Head Biomarkers and Clinical Bioanalyses,
**Sanofi R&D**

**DMITRI MIKHAILOV**
Director,
**Novartis**

**KIRI GRANGER** Chief Scientific Officer,
**Monument Therapeutics**

**JOHN LE QUESNE**
Professor in Molecular Pathology,
**University of Glasgow**

**ANDREAS SPITZMÜLLER**
Director, Spatial Data Science,
**AstraZeneca**

Complimentary Guest Passes are Available

**Enquire**

# WELCOME TO
# Biomarkers & Precision Medicine 2025

Welcome to **Biomarkers & Precision Medicine 2025**, Oxford Global's flagship meeting bringing together key scientific leaders in pharma and biotech as well as renowned experts in academic and healthcare to discuss the latest scientific and technological advancements through a 2-day program.  Our combined agenda, which includes our Biomarkers, Digital Pathology & AI and Spatial Biology for Precision Medicine programmes offers intimate networking opportunities and curated content – ensuring you get the technical insights and strategic partners you need to meet your research & business goals.

Built with leading industry experts, our revamped programme highlights the most exciting biomarker, spatial biology and digital pathology research & technologies impacting R&D in 2025 – from early detection, translational biomarkers, CDx, AI, image analysis, through to bioinformatics, data analytics and interpretation. Plus, with coverage across all major disease areas, no matter what therapeutic area you're currently prioritizing, you'll gain tangible insights within your therapeutic programmes therefore improving the probability of success and accelerating precision medicine.

## Benefits of Attending

**Gain invaluable insights into the latest advancements in early detection technologies**, translational medicine and CDx with unique case studies across multiple therapeutic areas. Key opinion leaders will be presenting on oncology, IO, immunology, cardiovascular, neuroscience and more.

**Discuss the latest innovations in navigating regulatory barriers in clinical trials, CDx and complex biomarkers.** From in vitro diagnostics regulations and quality testing through to how regulators can support development and adoption.

**Analyze the newest spatial multi omics tools, techniques & approaches** and learn how they are poised to fuel the next wave of biomedical innovation. Presentations will delve into translating spatial imaging techniques & approaches into the clinic, multi-modality processing, and case studies from various spatial multi-omics.

**Take a deep dive into AI image analysis imaging in digital pathology and spatial biology** alongside bioinformatics, data analytics and interpretation. Key opinion leaders will be providing insights into, computational pathology, algorithm design, overcoming challenges in data acquisition and analysis and integrating AI into your workflows.

**Gain comprehensive insights into utilizing spatial biology & digital pathology in pharma.** Hear how Spatial Biology is driving forward biomarker and drug target discovery as well as diagnostic and therapeutic innovation.

Book Now

# Network and Knowledge-share

**1,000+ VPs, Directors & Heads** from leading pharma & biotech companies, academic research institutions, healthcare and regulatory representatives in the following specialisms and more:

- Precision Medicine
- Pre-Clinical
- Translational Medicine
- Clinical Diagnostics
- Clinical Biomarkers
- Clinical Development
- Biomarker Sciences
- Clinical Operations
- Companion Diagnostics
- Molecular Diagnostics

- Regulation
- Liquid Biopsies
- Early Detection Technologies
- Multiplex Technologies
- Digital Pathology
- Computational Pathology
- Pathology
- Immunohistochemistry
- Histopathology
- Toxicology & Safety Sciences

- Lab Transformation
- Image Analysis
- AI/ML
- Bioinformatics
- Data Analysis / Integration
- Spatial Multi-Omics
- Spatial Analysis
- Spatial Profiling

**Formal and informal meeting opportunities** offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Biomarker Discovery
- Biomarker Verification
- Biomarker Testing
- Biomarker Analysis
- Assay Kits & Platforms
- Immunoassays
- Multiplex Tools
- Companion Diagnostics
- Diagnostics Tools
- Regulation

- Clinical Outsourcing
- Contract Research
- Detection Technologies
- Liquid Biopsies
- Proteomics
- Metabolomics
- Flow Cytometry
- Precision Medicine
- Digital Pathology Hardware
- Digital Pathology Software

- Cloud Computing / Storage
- Image Analysis
- Spatial Profiling
- Spatial Technologies
- Spatial Informatics
- Sample Preparation
- Imaging Tools
- Bioinformatics
- Data Analysis

## Attended by these companies & many more:



AstraZeneca • NOVARTIS • Merck • MONUMENT THERAPEUTICS • sanofi • Johnson&Johnson Innovative Medicine

gsk GlaxoSmithKline • Crescendo biologics • MSD • novo nordisk • Pfizer • Imperial College London

University of Glasgow • Adaptimmune TRANSFORMING T CELL THERAPY • MUNA THERAPEUTICS • CATAPULT Cell and Gene Therapy • MDC MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT • AARHUS UNIVERSITY

UNIVERSITY OF OXFORD • CANCER RESEARCH UK • dkfz. • KU LEUVEN • ENGITIX THERAPEUTICS • EMBL

Book Now

# Drive Innovation & Accelerate Research

## Platinum Sponsor

labcorp

## Gold Sponsors

10x GENOMICS

AKOYA BIOSCIENCES
THE SPATIAL BIOLOGY COMPANY

ALMAC

ariadne.ai

CellCarta

DECIPHEX

DISCOVERY LIFE SCIENCES

IRON MOUNTAIN

Leica MICROSYSTEMS

Lunaphore
a bio-techne brand

Olink

Personalis

PRECISION for medicine

Q² Solutions

SAPIENT

STANDARD BIOTOOLS

## Silver Sponsors

ARC

BIOIVT
ELEVATING SCIENCE

Burning Rock Dx

CONCEPT LIFE SCIENCES

FOUNDATION MEDICINE

HOLOGIC Diagenode

MERCK

mission bio

NEO GENOMICS

Quanterix
Discovery Fueled by Ultra-Sensitivity

seer

SURFIX diagnostics

synexa Life Sciences

vizgen

ZEISS

## Bronze Sponsors

ALAMAR BIOSCIENCES

BIOGNOSYS
NEXT GENERATION PROTEOMICS

Diaceutics

ICON

MEDTECH TO MARKET

Miltenyi Biotec

opentrons

RARECYTE

## Network & Programme Sponsors

AIRA MATRIX

BioLizard

CROWN BIOSCIENCE

NOF

PROSCIA

# Explore Curated & Insightful Content

**Biomarkers & Precision Medicine 2025** features 2 days of cutting-edge presentations and knowledge-sharing. The event will include over 120 industry insights, sponsored presentations & interactive discussion sessions across three programmes.

**Biomarkers**

### DAY ONE | TRACK 1
### Biomarkers Identification, Validation in Oncology, Immuno-Oncology & Immunology

- Biomarker discovery tools and technologies
- Biomarker strategies for patient identification
- Biomarkers to detect, predict / monitor response to treatment
- Check point inhibitors and dual therapies in immuno-oncology
- Scientific & regulatory considerations for the analysis and validation of biomarkers

### DAY ONE | TRACK 2
### Diagnostic Biomarkers & Regulations

- IVDR Regulations and their impact
- Liquid biopsy biomarkers for disease monitoring, multi-cancer screening & early detection /ultra-sensitivity/ MRD
- Latest technologies in detection and molecular characterization of: CTCs; cfDNA, ctDNA, circulating extracellular RNA; exosomes & microvesicles
- Companion diagnostic development - parallel diagnostic and drug approval strategies
- Diagnostic-driven therapies: towards the clinic with optimised market access & patient adoption
- Developing nextgen diagnostic methods & approaches including point-of-care diagnostics
- Delivering precision medicine for respiratory, autoimmune, immunology diseases & neuroscience

### DAY ONE | TRACK 3
### Biomarkers for Clinical Development

- Transforming clinical development through biomarker driven clinical trial design and data analysis
- Exploratory /clinical endpoint biomarkers needed to support clinical trials
- Biomarker development gene therapy- patient responses and histology
- Use of cellular, transcriptomic and proteomic biomarkers in clinical trials

### DAY ONE | TRACK 4
### Genomic & Multi-Omic Approaches in Biomarkers Discovery and Development

- Precision medicine approaches for personalized therapies
- Precision oncology and molecular profiling
- Biofluid-based molecular biomarkers: cfDNA, ctDNA and CTCs
- Validating and verifying genomic markers in preclinical drug development
- Biomarkers guiding precision medicine based on genomics and proteomics analysis of clinical trials

### DAY TWO | TRACK 1
### Biomarkers Identification & Validation: Neuroscience & Co-Morbidity

- Novel case studies & strategies in biomarker discovery, analysis and validation in neuroscience / CNS / neuropsychiatric disorders
- Imaging, digital and liquid biomarkers
- Technologies and approaches to improve target engagement, early diagnostic biomarkers and how best to incorporate biomarkers into drug development, patient stratification and clinical trials in neuroscience

### DAY TWO | TRACK 2
### New & Emerging Biomarker Technologies for Biomarker Analysis & Data Science

- Technology approaches, techniques & analysis - flow cytometry, mass spectrometry, proteomics, metabolomics
- Biomarker assay optimization & validation
- Integrating multi-omics data

Part 2 – Data Science
- Addressing the gap between AI, RWE / FAIR data & biomarker data analysis in pharma
- Application and integration of AI/ML for biomarker discovery, diagnostics, prognostics, patient stratification & precision medicine

### DAY TWO | TRACK 3
### Biomarkers for Clinical Trials

- Translational biomarkers from preclinical to clinical phase studies
- The role of safety and efficacy biomarkers in translation
- Patient profiling and biosignatures in clinical development
- Patent engagement in biomarker development
- Patient centric biomarkers in clinical trials
- Transitioning complex biomarkers into the clinic

### DAY TWO | TRACK 4
### Biomarkers for Diagnostics & Precision Medicine

- Liquid biopsy biomarkers for disease monitoring, multi-cancer screening & early detection /ultra-sensitivity/ MRD
- Latest technologies in detection and molecular characterization of: CTCs; cfDNA, ctDNA, circulating extracellular RNA; exosomes & microvesicles
- Biofluid biomarkers for early disease detection
- Delivering precision medicine for respiratory, autoimmune, immunology diseases & neuroscience

**Book Now**

# Explore Curated & Insightful Content

## Spatial Biology for Precision Medicine

**DAY ONE | TRACK 1**
### Spatial Multi Omics Tools, Techniques & Approaches

- Translating spatial imaging techniques & approaches into clinics
- Transcriptomics, proteomics, genomics & metabolomics breakthrough tools, techniques & approaches for Precision Medicine
- Single-cell transcriptome / RNA-seq
- Multi-modality processing
- Discovery of robust next-generation diagnostics & biomarkers that are key to designing precision medicine treatments

**DAY ONE | TRACK 2**
### Spatial Biology in Pharma & Translational Drug Research

- Accelerating the discovery & characterization of biomarkers and drug targets using spatial tools
- Tailoring precision medicine approaches by considering spatial distribution of drug targets
- Impacting disease research – informing assessment of treatment and action mechanisms / deciphering dynamics of cell interactions
- Feasibility & scalability of various platforms

**DAY TWO | TRACK 1**
### AI Image Analysis, Imaging & Spatial Bioinformatics, Data Analytics & Interpretation

- Tissue imaging & analysis using advanced spatial profiling techniques and AI guided technology
- Imaging data analysis / how to set a spatial experiment
- Relevant spatial parameters in different model systems
- Label free imaging technologies – imaging mass spec
- Algorithm design for spatial data
- Spatial multiplexed imaging for disease characterization
- Intersection of Digital pathology & spatial biology
- Computational methods to assist in the identification, classification and visualization of complex multi model datasets
- Data access, interoperability & standardization
- Overcoming challenges in multi-omic data acquisition & analysis
- Data integration, visualization, handling & insight
- Cell-cell interaction

**DAY TWO | TRACK 2**
### Applications of Spatial Research & Technologies in Biology

- Accelerating the discovery of novel biomarkers and drug targets using spatial imaging
- Case studies from the areas of:
  » Personalised / precision medicine
  » Oncology & Tumour microenvironment
  » Cardiovascular, Immunological, Infectious, Neurobiology/ neurodegenerative diseases and regenerative medicine
- Part 2 – Spatial Technologies for Clinical Development
- Diagnostics applications of spatial and multi-omics tissue analysis
- Translating spatial imaging techniques & approaches into clinics
- Supporting clinical trials & patient monitoring

## Digital Pathology & AI

**DAY ONE | TRACK 1**
### Image Analysis & AI

- Examining the latest developments in imaging technologies
- Advances in image quality and processing
- Exploring both manual and fully-automated image analysis and pattern recognition
- Quality assurance, control and improvement
- Validation methods
- User experience of /integration of AI into their workflows
- Pathologists perspective – using and working with AI
- Image format standardization
- Quantitative image analysis research and applications of AI

**DAY ONE | TRACK 2**
### Digital Pathology Implementation, Strategy & Applications

- Advances, challenges, benefits & future developments of Digital Pathology, and the implications for pathology practice
- Analysing the business case for digital pathology
- Procurement in multi-site environments
- User experience of converting to/integration of digital pathology
- Ethical viewpoint of AI in pathology
- Laboratory accreditation and regulations

**DAY TWO | TRACK 1**
### Computational Pathology & AI

- Implementing AI based precision pathology
- Advancing machine and deep learning algorithms
- Improving WSI workflow efficiency
- Pathology PACS and informatics
- Cloud computing / storage solutions
- Computational Pathology in Precision Oncology
- Deep learning application for digital biomarker discovery
- Ground truth data and technology for biomarker assessment

**DAY TWO | TRACK 2**
### Utilizing Digital Pathology & AI in Pharma Research

- Digitizing toxicology
- Digital image analysis in drug discovery
- AI algorithms for tissue-based endpoints
- AIML solutions for Biomarker discovery, detection, quantification and use in patient selection
- Case studies in:
- Oncology, MASH, neurology, Clinical trials support; diagnosis / diagnostics; next generation sequencing; biomarker analysis / research / quantification; tissue-based research / imaging; digital Biobanking, AI

Book Now

# Gain Expertise from Thought Leaders

**TIM AITMAN**
Director of the Centre for Genomic and Experimental Medicine, University of Edinburgh, Institute of Genetics and Cancer

**CHRIS CHAMBERLAIN**
Executive Director Precision Medicine Discovery and Development, AstraZeneca

**HENOCH HONG**
Associate Director, Merck Healthcare KGaA

**GABRIELA KRAMER-MAREK**
Associate Professor of Molecular Imaging Institute of Cancer Research

**DAVID KRIGE**
Head Of Translational Sciences, Accession Therapeutics

**ANDREW PIERCE**
Vice President, Translational Biology, Crescendo Biologics

**THOMAS JENSEN**
Chief Executive Officer, Allarity Therapeutics

**DMITRI MIKHAILOV**
Director, Novartis

**KIRA HOLMSTROM**
Head Of Biomarker Research, Herantis Pharma

**ALEXANDRA SEVKO**
Director, Translational Research, Prokarium

**KIRI GRANGER**
Chief Scientific Officer, Monument Therapeutics

**GADY COJOCARA**
Director of Biomarker Research/ Computational Discovery, Compugen

**VALERIE TALY**
Group Leader and CNRS Research Director, INSERM

**DONNA FINCH**
Head of Translational and Clinical Science, Alchemab Therapeutics

**AIDA SANTAOLALLA**
Senior Epidemiologist and Senior Data Scientist, King's College London

**CHRISTOPHER PETERS**
Clinical Senior Lecturer and Consultant Upper GI and General Surgeon, Imperial College London

**STEVEN PICCOLI**
Head Clinical Biomarkers, SPARC

**PATRICK FIVEY**
Director of Precision Medicine Policy, AstraZeneca

**DEBAYAN MUKHERJEE**
Principal Scientist, Spatial Multiplex Imaging, In Vitro/ In Vivo Translation Research - Pharma R&D, GSK

**THOMAS HACH**
Senior Clinical Development Medical Director, Novartis

**ANDERS STAHLBERG**
Professor Clinical Genomics, Gothenburg University

**EMMA LEIRE**
Head of Translational Science Immune Monitoring, Achilles Therapeutics

**MARIA UDRISTE SOCEA**
Senior Scientist, AstraZeneca

**JULIA JONES**
Scientific Manager, Cancer Research UK, Cambridge Institute

**MARTIN ISABELLE**
Associate Director, Tumour Profiling and Mechanistic Biology, Translational Sciences, Adaptimmune

**WEI-TING CHEN**
Head of Discovery Biology, Muna Therapeutics

**ANDREAS SPITZMÜLLER**
Director, Spatial Data Science, AstraZeneca

**NIK MATTHEWS**
Head of Imperial BRC Genomics Facility, Imperial College London

**MICHAEL EYRES**
Lead Scientist - Spatial Biomarkers, Medicines Discovery Catapult

**STEFAN KEMPA**
Group Leader, Head of Integrative Metabolomics and Proteomics, MDC Berlin

**GARETH MUIRHEAD**
Associate Director, Lead Bioinformatician, Engitix Therapeutics

**RAFFAELE CALOGERO**
Professor of Molecular Biology, University of Torino

Book Now

# Unleashing Innovation & Collaboration in Biomarkers Research & Development

**Join engaging presentations featured in our innovation and collaboration tracks**, inspiring growth and creating space for collaboration opportunities for all who attend. The core attendee mix includes early-stage and emerging biotech or (academic) spinoff companies developing their own platforms or technologies with fewer than 30 employees.

**Featuring Attendees from Biotech and/or (Academic) Spinoff Companies Interested In:**

✓ Seeking collaboration partners with pharma and solution providers.

✓ Discovering new investment opportunities with pharma.

✓ Learning about the latest industry trends & challenges.

✓ Keeping updated with new innovations and technology solutions.

✓ Showcasing their company profile to a targeted and engaged audience.

**Format:**

The Innovation & Collaboration track will be comprising of 10-minute presentations and focused panel discussion sessions, encouraging networking, facilitating collaborations & showcasing emerging innovations in precision medicine

---

**Poster Presentation Awards at Biomarkers & Precision Medicine 2025**

The Biomarkers & Precision Medicine Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.

Please submit your poster presentation by no later than 25th August 2025 in one of the below categories:

- • Biomarkers in Therapeutics
- • Biomarkers in Diagnostics
- • Biomarkers in Clinical Trials & Precision Medicine
- • Spatial Biology Applications
- • Image Analysis & AI
- • Digital Pathology Applications

Book Now

# Discuss Key Solutions With Leading Service Providers

Experience an international exhibition showcasing cutting-edge technologies and services from premier providers in the scientific field.



**STAGE**

**LIFTS TO CONFERENCE ROOMS**

## ZONE A: BIOMARKERS

| | | | |
|---|---|---|---|
| 1. | 3x2m | 31. | 3x2m |
| 2. | 3x2m | 32. | 3x2m |
| 3. | Proscia | 33. | 3x2m |
| 4. | 3x2m | 34. | 3x2m |
| 5. | 3x2m | 35. | 3x2m |
| 6. | 3x2m | 36. | 3x2m |
| 7. | 3x2m | 37. | Mission Bio Inc. |
| 8. | 3x2m | 38. | Alamar Biosciences |
| 9. | 3x2m | 39. | 3x2m |
| 10. | 3x2m | 40. | 3x2m |
| 11. | 3x2m | 41. | Discovery Life Sciences |
| 12. | 3x2m | 42. | BioIVT |
| 13. | 3x2m | 43. | 3x2m |
| 14. | 3x2m | 44. | 3x2m |
| 15. | 3x2m | 45. | Olink Proteomics |
| 16. | Synexa Life Sciences | 46. | Biognosys AG |
| 17. | 3x2m | 47. | Burning Rock Dx LLC |
| 18. | 3x2m | 48. | 3x2m |
| 19. | 3x2m | 49. | CellCarta |
| 20. | Quanterix | 50. | Medtechtomarket Ltd |
| 21. | 3x2m | 51. | 3x2m |
| 22. | 3x2m | 52. | Labcorp |
| 23. | Personalis | 53. | Labcorp |
| 24. | Almac | 54. | Q2 Solutions (RBM) |
| 25. | 3x2m | 55. | ICON Clinical Research |
| 26. | Concept Life Sciences | 56. | Sapient |
| 27. | Seer | 57. | Surfix Diagnostics |
| 28. | ARC Regulatory | 58. | NOF Europe |
| 29. | Foundation Medicine | 59. | 3x2m |
| 30. | Crown Bioscience | | |

## ZONE B: DIGITAL PATHOLOGY

| | | | |
|---|---|---|---|
| 1. | Deciphex | 8. | 3x2m |
| 2. | 3x2m | 9. | 3x2m |
| 3. | 3x2m | 10. | 3x2m |
| 4. | 3x2m | 11. | 3x2m |
| 5. | 3x2m | 12. | 3x2m |
| 6. | 3x2m | 13. | 3x2m |
| 7. | 3x2m | 14. | 3x2m |

## ZONE C: SPATIAL BIOLOGY

| | | | |
|---|---|---|---|
| 1. | 3x2m | 12. | 3x2m |
| 2. | 3x2m | 13. | 3x2m |
| 3. | 3x2m | 14. | 3x2m |
| 4. | Standard BioTools | 15. | 3x2m |
| 5. | 10X Genomics | 16. | Leica Microsystems |
| 6. | 3x2m | 17. | Lunaphore |
| 7. | 3x2m | 18. | NeoGenomics |
| 8. | Miltenyi Biotech | 19. | Carl Zeiss Microscopy |
| 9. | 3x2m | 20. | Akoya Biosciences |
| 10. | 3x2m | 21. | 3x2m |
| 11. | 3x2m | 22. | 3x2m |

## ZONE D: START-UP ZONE

| | | | |
|---|---|---|---|
| 1. | 1x1m | 2. | 1x1m |
| 3. | 1x1m | 4. | 1x1m |
| 5. | 1x1m | 6. | 1x1m |

## KEY

Refreshments | Booth Taken | Posters

**Book Now**

## Interested in Sponsoring?

Become a driving force in accelerating the next generation of personalized treatments. Biomarkers & Precision Medicine 2025 offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, & academic experts.

**More Info**